Precision Dose, a South Beloit, Ill.-based prescription drug supplier, is recalling five lots of its ranitidine oral solution after finding a potential human carcinogen.
Precision Dose initiated the recall in response to Amneal's recall, which included lots repackaged by Precision Dose.
The drugmaker found levels of N-Nitrosodimethylamine in the product higher than the FDA accepts.
Consumers, distributors and retailers with the affected lots should stop use and call Precision dose to obtain a return packet.
Precision Dose has not received any adverse event reports related to the recall.
Read the full news release here.
More articles on pharmacy:
AHA, CVS Health backed secretive anti-pharma group
EpiPen, Humira among drugs Warren wants to regulate
31 drugmakers at high risk for bankruptcy in 2020